Valuation : Insmed Incorporated

Market Cap 27.58B 23.73B 22.33B 20.4B 38.16B 2,604B 38.26B 264B 102B 1,336B 104B 101B 4,304B P/E 2026 *
-77.3x
P/E 2027 * 141x
Enterprise Value 26.95B 23.19B 21.82B 19.93B 37.28B 2,544B 37.38B 258B 100B 1,305B 101B 98.98B 4,205B EV / Sales 2026 *
14.9x
EV / Sales 2027 * 9.16x
Free-Float
99.49%
Yield 2026 *
-
Yield 2027 * -
1 day-0.31%
1 week+6.54%
Current month+3.67%
1 month+27.54%
3 months+34.04%
6 months-12.04%
Current year-27.44%
1 week 117.51
Extreme 117.51
128.24
1 month 117.15
Extreme 117.15
135.5
Current year 90.39
Extreme 90.39
186.19
1 year 90.39
Extreme 90.39
212.75
3 years 21.92
Extreme 21.92
212.75
5 years 16.04
Extreme 16.04
212.75
10 years 10.21
Extreme 10.21
212.75
Manager TitleAgeSince
Chief Executive Officer 57 10/09/2012
Director of Finance/CFO 45 31/01/2020
Chief Tech/Sci/R&D Officer 62 19/12/2019
Director TitleAgeSince
Chairman 75 16/06/2009
Chairman 57 08/11/2018
Director/Board Member 72 29/05/2014
Date Insider Type Main position Quantity % Market Cap. Importance
17/08/26 Sell

Director

-5,000 0.0023%
10/08/26 Exercice

Chief Operating Officer

719,550 0.3320%
06/08/26 Exercice

Chief Technology Officer

81,519 0.0376%
Change 5-day change 1-year change 3-year change Capi.($)
-0.31%+6.54%-12.96%+378.92% 27.58B
-1.79%-2.27%+43.23%+88.96% 67.98B
-2.06%-0.18%+39.67%+86.44% 64.94B
+0.86%+1.65%-7.74%-14.95% 26.06B
-3.00%-2.90%+33.13%+12.54% 25.74B
-1.46%+0.42%+23.61%-18.61% 20.09B
-2.96%-15.21%+216.20%+368.10% 17.16B
-1.49%-4.88%-6.60%+531.89% 14.92B
-0.20%+8.37%+55.78%+164.98% 14.62B
+2.77%+28.22%-32.24%+1,021.34% 14.04B
Average -0.96%+3.05%+35.21%+261.96% 29.31B
Weighted average by Cap. -1.31%+1.52%+34.99%+179.70%

Financials

2026 *2027 *
Net sales 1.81B 1.55B 1.46B 1.34B 2.5B 171B 2.51B 17.28B 6.71B 87.5B 6.78B 6.64B 282B 2.89B 2.48B 2.34B 2.13B 3.99B 272B 4B 27.61B 10.71B 140B 10.84B 10.6B 450B
Net income -349M -301M -283M -258M -483M -32.99B -485M -3.34B -1.3B -16.92B -1.31B -1.28B -54.52B 211M 182M 171M 156M 293M 19.96B 293M 2.02B 785M 10.24B 794M 777M 33B
Net Debt -632M -544M -512M -467M -874M -59.65B -877M -6.04B -2.35B -30.61B -2.37B -2.32B -98.6B -1.16B -995M -936M -855M -1.6B -109B -1.6B -11.07B -4.29B -56.03B -4.34B -4.25B -180B
Logo Insmed Incorporated
Insmed Incorporated is a global biopharmaceutical company. It is advancing a diverse range of approved and mid- to late-stage investigational medicines and drug discovery. Its advanced programs are in pulmonary and inflammatory conditions, including a therapy approved in the United States, Europe, and Japan to treat a chronic, debilitating lung disease. Its pre-clinical research programs encompass a range of technologies and modalities, including gene therapy, AI-driven protein engineering, protein manufacturing, RNA end-joining, and synthetic rescue. Its first commercial product, ARIKAYCE (amikacin liposome inhalation suspension), is used for the treatment of Mycobacterium avium complex lung disease as part of a combination antibacterial drug regimen for adult patients with limited or no alternative treatment options. Its pipeline includes clinical-stage programs, brensocatib, TPIP, and INS1201 and pre-clinical research programs. Its INS1148 is an investigational monoclonal antibody.
Employees
1,664
Date Price Change Volume
04/09/26 $126.29 -0.31% 1,802,693
03/09/26 $126.68 +0.04% 1,885,698
02/09/26 $126.63 +4.21% 1,998,834
01/09/26 $121.51 -0.25% 1,419,286
31/08/26 $121.82 +2.77% 2,390,325
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
A
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
23
Last Close Price
126.29USD
Average target price
200.18USD
Spread / Average Target
+58.51%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. INSM Stock